Clinical Trial Results: Positive or negative results from Seer's Proteograph clinical trials directly impact investor confidence and stock price.

FDA Approvals: Anticipation of or actual FDA approval for Seer's technology significantly influences the perceived value and future revenue potential.

Market Conditions: General economic downturns or upturns, particularly within the biotechnology sector, affect investor sentiment towards Seer.

Competition: The emergence of new competitors or the advancement of existing technologies in proteomics can influence Seer's market share and stock price.

Partnerships/Collaborations: Agreements with pharmaceutical companies or research institutions boost credibility and future revenue projections.

Financial Performance: Revenue growth, profitability, and cash flow impact investor perceptions of Seer's long-term viability.

Investor Sentiment: Overall market mood and investor confidence in growth stocks or the biotech industry in general affects Seer's valuation.

Regulatory Changes: Changes in government regulations regarding proteomics or diagnostics could impact Seer's business and stock price.

Technological Advancements: Breakthroughs in proteomics technology, whether by Seer or its competitors, influence the perceived value of Seer's platform.